|
FDA Reclassifies Clinical Hold on Repros’ Mid-Stage Endometriosis Trial
The FDA reclassified its clinical hold on Repros Therapeutics’ Proellex and will now allow the company to conduct a Phase II trial of low-dose Proellex as a treatment for endometriosis.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives